Valiant LaboratoriesNSE:VALIANTLAB -0.06%51 Current Ratio is 1.91 as of Mar. 2026, which is 40% below its 10-year median of 3.20. GuruFocus rates NSE:VALIANTLAB with a GF Score™ of 51/100 and a GF Value™ of ₹103.25 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 998 Drug Manufacturers companies, Valiant Laboratories ranks worse than 52.1% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Valiant Laboratories's current ratio for the quarter that ended in Mar. 2026 was 1.91.
Valiant Laboratories has a current ratio of 1.91. It generally indicates good short-term financial strength.
The historical rank and industry rank for Valiant Laboratories's Current Ratio or its related term are showing as below:
NSE:VALIANTLAB'
s Current Ratio Range Over the Past 10 Years
Min: 1.91 Med: 3.2 Max: 7.76
Current: 1.91
During the past 6 years, Valiant Laboratories's highest Current Ratio was 7.76. The lowest was 1.91. And the median was 3.20.
NSE:VALIANTLAB's Current Ratio is ranked worse than 52.1% of 998
companies
in the Drug Manufacturers industry
Industry Median: 1.995
vs NSE:VALIANTLAB: 1.91
Valiant Laboratories (NSE:VALIANTLAB) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Valiant Laboratories Current Ratio Related Terms
Valiant Laboratories Current Ratio Historical Data
* Premium members only.
The historical data trend for Valiant Laboratories's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Valiant Laboratories's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Valiant Laboratories Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Valiant Laboratories's Current Ratio distribution charts can be found below:
* The bar in red indicates where Valiant Laboratories's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Valiant Laboratories (NSE:VALIANTLAB) has a Current Ratio of 1.91 as of Mar. 2026. This is 40% below median its historical median of 3.20. Over the past decade, Valiant Laboratories' Current Ratio has ranged from 1.91 to 7.76. According to the industry distribution chart, Valiant Laboratories ranks #520 out of 998 companies in the Drug Manufacturers industry, placing it in the top 52.1%.
Is Valiant Laboratories' Current Ratio too high?
Valiant Laboratories' current Current Ratio of 1.91 is 40% below median its 10-year median of 3.20. Over the past 10 years, this metric has ranged from a low of 1.91 to a high of 7.76. The Drug Manufacturers industry median Current Ratio is 2.00. Valiant Laboratories' value of 1.91 is 4.3% below this industry median. Based on the distribution chart, Valiant Laboratories ranks #520 out of 998 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Valiant Laboratories has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Valiant Laboratories' Current Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Valiant Laboratories ranks #520 out of 998 companies for Current Ratio. This places Valiant Laboratories in the lower half of its industry. The industry median Current Ratio is 2.00. Valiant Laboratories' value of 1.91 is 4.3% below this benchmark. Historically, Valiant Laboratories' own Current Ratio has ranged from 1.91 to 7.76 over the past decade. While the company's 10-year median is 3.20 vs. the industry median of 2.00, Valiant Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 998 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Valiant Laboratories's current Current Ratio of 1.91 is 4.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Valiant Laboratories's current Current Ratio is 1.91, which is 40% below median its own 10-year median of 3.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valiant Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Valiant Laboratories (NSE:VALIANTLAB) is currently considered Possible Value Trap. The stock's GF Value™ is ₹103.25, compared to a current price of ₹68.00 — trading 34.1% below its estimated fair value. The current Current Ratio is 1.91, which is 40% below median its 10-year median of 3.20 and 4.3% below the Drug Manufacturers industry median of 2.00. Valiant Laboratories' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Valiant Laboratories (NSE:VALIANTLAB), the current Current Ratio is 1.91 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Valiant Laboratories (NSE:VALIANTLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Valiant Laboratories stock appears to be undervalued.
The current stock price of ₹68.00 is trading 34.1% below its estimated GF Value™ of ₹103.25.
GuruFocus considers Valiant Laboratories to be Possible Value Trap.
Key valuation signals for NSE:VALIANTLAB:
Current Ratio: 1.91 (40% below median its 10-year median of 3.20)
GF Value™: ₹103.25 vs. price of ₹68.00 (34.1% below fair value)
Industry Position: 4.3% below the Drug Manufacturers median (#520 of 998)
No single metric tells the full story. See the NSE:VALIANTLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Valiant Laboratories Ltd is an Active Pharmaceutical Ingredient (API)/Bulk Drug manufacturing company with having focus on manufacturing Paracetamol. Paracetamol is one of the widely used analgesics globally and is recommended as the first-line therapy in pain conditions by the World Health Organization. Paracetamol has several applications such as usage in the treatment of headaches, muscle aches, arthritis, backaches, toothaches, colds, and fever. It manufactures Paracetamol in various grades such as IP/BP/EP/USP, as per the pharmacopeia requirements of its customers.
51GF Score
Get the complete analysis for NSE:VALIANTLAB
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:VALIANTLAB has been successfully added to your 
